These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 7591445)

  • 21. Long-term maintenance therapy with cyclosporine and posttreatment survey in severe psoriasis: results of a multicenter study. German Multicenter Study.
    Mrowietz U; Färber L; Henneicke-von Zepelin HH; Bachmann H; Welzel D; Christophers E
    J Am Acad Dermatol; 1995 Sep; 33(3):470-5. PubMed ID: 7657870
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intermittent cyclosporin A treatment of severe plaque psoriasis. Long-term follow-up of 26 patients.
    Peluso AM; Bardazzi F; Tosti A; Varotti C
    Acta Derm Venereol Suppl (Stockh); 1994; 186():90-1. PubMed ID: 8073851
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low-dose (1.25 mg/kg) cyclosporin A: treatment of psoriasis and investigation of the influence on lipid profile.
    Meffert H; Bräutigam M; Färber L; Weidinger G
    Acta Derm Venereol; 1997 Mar; 77(2):137-41. PubMed ID: 9111826
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Etanercept reduces symptoms and severity of psoriasis after cessation of cyclosporine therapy: results of the SCORE study.
    Micali G; Wilsmann-Theis D; Mallbris L; Gallo G; Marino V; Brault Y; Germain JM
    Acta Derm Venereol; 2015 Jan; 95(1):57-61. PubMed ID: 24682319
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis: Subgroup analysis of Latin American patients in the phase 3 randomized UNCOVER-3 study.
    Valenzuela F; de la Cruz Fernandez C; Galimberti RL; Gürbüz S; McKean-Matthews M; Goncalves L; Romiti R
    Actas Dermosifiliogr; 2017; 108(6):550-563. PubMed ID: 28342534
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structure.
    Lowe NJ; Wieder JM; Rosenbach A; Johnson K; Kunkel R; Bainbridge C; Bourget T; Dimov I; Simpson K; Glass E; Grabie MT
    J Am Acad Dermatol; 1996 Nov; 35(5 Pt 1):710-9. PubMed ID: 8912566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis.
    Maza A; Montaudié H; Sbidian E; Gallini A; Aractingi S; Aubin F; Bachelez H; Cribier B; Joly P; Jullien D; Le Maître M; Misery L; Richard MA; Ortonne JP; Paul C
    J Eur Acad Dermatol Venereol; 2011 May; 25 Suppl 2():19-27. PubMed ID: 21388455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of etanercept therapy on psoriasis symptoms in patients from Latin America, Central Europe, and Asia: a subset analysis of the PRISTINE trial.
    Kemeny L; Amaya M; Cetkovska P; Rajatanavin N; Lee WR; Szumski A; Marshall L; Mahgoub EY; Aldinç E
    BMC Dermatol; 2015 May; 15():9. PubMed ID: 25994179
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined treatment with low-dose cyclosporine and calcipotriol/betamethasone dipropionate ointment for moderate-to-severe plaque psoriasis: a randomized controlled open-label study.
    Vena GA; Galluccio A; Pezza M; Vestita M; Cassano N
    J Dermatolog Treat; 2012 Aug; 23(4):255-60. PubMed ID: 21756153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A retrospective analysis of combination methotrexate-cyclosporine therapy in moderate-severe psoriasis.
    Mohanan S; Ramassamy S; Chandrashekar L; Thappa DM
    J Dermatolog Treat; 2014 Feb; 25(1):50-3. PubMed ID: 23469768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis.
    Papp KA; Menter MA; Raman M; Disch D; Schlichting DE; Gaich C; Macias W; Zhang X; Janes JM
    Br J Dermatol; 2016 Jun; 174(6):1266-76. PubMed ID: 26800231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cyclosporine and psoriasis: experience with 14 patients].
    Gajardo J
    Rev Med Chil; 1993 Dec; 121(12):1411-5. PubMed ID: 8085065
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of a fixed-dose cyclosporin microemulsion (100 mg) for the treatment of psoriasis.
    Shintani Y; Kaneko N; Furuhashi T; Saito C; Morita A
    J Dermatol; 2011 Oct; 38(10):966-72. PubMed ID: 21545506
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Algorithm to select optimal systemic anti-psoriatic drugs in relation with patients' Psoriasis Area and Severity Index score for plaque psoriasis.
    Bae SH; Yun SJ; Lee JB; Kim SJ; Won YH; Lee SC
    J Dermatol; 2016 Jun; 43(6):643-9. PubMed ID: 26598783
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study.
    Smith CH; Jackson K; Bashir SJ; Perez A; Chew AL; Powell AM; Wain M; Barker JN
    Br J Dermatol; 2006 Jul; 155(1):160-9. PubMed ID: 16792769
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
    Lebwohl MG; Kircik L; Callis Duffin K; Pariser D; Hooper M; Wenkert D; Thompson EH; Yang J; Kricorian G; Koo J
    J Am Acad Dermatol; 2013 Sep; 69(3):385-92. PubMed ID: 23643256
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
    Reich K; Armstrong AW; Foley P; Song M; Wasfi Y; Randazzo B; Li S; Shen YK; Gordon KB
    J Am Acad Dermatol; 2017 Mar; 76(3):418-431. PubMed ID: 28057361
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
    Mazzotta A; Esposito M; Costanzo A; Chimenti S
    Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of low-dose cyclosporin A in psoriasis: results of dose-finding studies.
    Timonen P; Friend D; Abeywickrama K; Laburte C; von Graffenried B; Feutren G
    Br J Dermatol; 1990 Jun; 122 Suppl 36():33-9. PubMed ID: 2196082
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical outcome evaluation following cyclosporine a treatment in moderate to severe psoriasis: a retrospective study.
    Colombo D; Flori L; Altomare G; Aste N; Sgarbi S
    Int J Immunopathol Pharmacol; 2010; 23(1):363-7. PubMed ID: 20378025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.